Previous 10 | Next 10 |
Cabaletta Bio press release (NASDAQ:CABA): Q1 GAAP EPS of -$0.45. As of March 31, 2022, Cabaletta had cash, cash equivalents and investments of $109.2 million, compared to $122.2 million as of December 31, 2021. For further details see: Cabaletta Bio GAAP EPS of -$0.45
– DesCAARTes™ trial clinical and translational data from cohorts A3 and A4 and 28-day safety data from cohort A5 expected to be presented at upcoming scientific meetings in mid-2022 – – Multiple ...
PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that data from its two lead programs, DSG3-CAA...
Gainers: Nkarta NKTX +111%. ERYTECH Pharma ERYP +44%. Rubius Therapeutics RUBY +34%. Redbox Entertainment RDBX +32%. Sky Harbour Group (SKYH) +28%. Sunshine Biopharma SBFM +26%. Cabaletta Bio (CABA) +23%. Cango CANG +22%. WISeKey International (WKEY) +19%. Veru V...
San Diego, California--(Newsfile Corp. - April 12, 2022) - The Shareholders Foundation, Inc. announced that a deadline is coming up on April 29th in the lawsuit that was filed for certain investors in (NASDAQ: CABA) shares. Investors who have losses of over $50,000 from their investment in sh...
Shares of Cabaletta Bio Inc. (NASDAQ:CABA) traded today at $19.60, eclipsing its 52-week high. Approximately 7.5 million shares have changed hands today, as compared to an average 30-day volume of 201,000 shares. Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the ...
PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Gwendolyn Binder, Ph.D., President of S...
SAN DIEGO, CA / ACCESSWIRE / April 5, 2022 / The Shareholders Foundation, Inc. announced that a deadline is coming up on April 29th in the lawsuit that was filed for certain investors in shares of Cabaletta Bio, Inc. (NASDAQ:CABA). Investors who have losses of over $50,000 from their invest...
New York, New York--(Newsfile Corp. - March 21, 2022) - Levi & Korsinsky, LLP notifies investors in Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ: CABA) of a class action securities lawsuit. The lawsuit on behalf of Cabaletta investors has been commenced in the the United S...
Cabaletta Bio press release (NASDAQ:CABA): Q4 GAAP EPS of -$0.49 beats by $0.11. As of December 31, 2021, cash and cash equivalents and investments of $122.2 million, compared to $108.7 million as of December 31, 2020 For further details see: Cabaletta Bio GAAP EPS of -$0.49 beats by $0...
News, Short Squeeze, Breakout and More Instantly...
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtb...
2024-06-20 09:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both...